Initially Diagnosed:
2013
Current Diagnosis:
Relapsed, Refractory
Treatments Received:
Velcade, Revlimid, dexamethasone, autologous stem cell transplant, Darzalex, Kyprolis, Pomalyst and intrathecal chemotherapy, CAR-T
Andrew was diagnosed with multiple myeloma in 2013. Having never heard of myeloma, he began to educate himself about the disease, a process that continues to this day. Throughout his initial treatment, which proceeded from induction to stem cell transplant and then maintenance, Andrew continued to embrace the importance of exercise, riding his bike and going to the gym daily. He achieved a quick remission, which allowed him to go without treatment from March of 2016 until his relapse in 2023.
Andrew's relapse in December of 2023 presented new challenges because it reappeared not in his bone marrow, but in his central nervous system. This is an extremely rare form of myeloma for which there are no proven effective treatment regimens. His team of doctors designed a multi-faceted plan that included systemic and intrathecal chemotherapy followed by CAR T-cell therapy. Andrew now has resumed his normal life, which includes his continued dedication to exercise, raising awareness for myeloma and helping other myeloma patients.
